Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioids For Pediatric Cough: UCB Seeks Limits, Pressuring Other Sponsors

Executive Summary

UCB will make case for limiting use of Tussionex, its hydrocodone-containing antitussive, to patients 18 years and older at US FDA Pediatric Advisory Committee meeting, where panelists will consider the benefit/risk profile for all currently marketed opioid-containing cough treatments when used in children.

You may also be interested in...

Opioid Cough Restrictions: Pediatric Use, And Postmarket Studies, Likely Limited

US FDA advisory committee strongly recommends antitussives containing codeine or hydrocodone not be used by patients under age 18 years old, pointing to lack of modern evidence of benefit and known risks of respiratory depression and misuse. Expanding the contraindicated population could get some product sponsors off the hook for required pediatric studies.

Opioid Cough Medicines Might Face Complete Ban In Pediatric Patients

US FDA's Pediatric Advisory Committee sets meeting for meeting Sept. 11 to discuss the use of opioids with hydrocodone and codeine for treating pediatric cough.

Curtain Falls On Opana ER As Endo Agrees To US FDA Withdrawal Request

Company will cease manufacturing the extended-release oxymorphone formulation immediately and will not ship existing finished product after Sept. 1; decision to pull the opioid from the market heads off a fight with FDA, which sought withdrawal due intravenous abuse liability.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts